Financial Analysis: Parnell Pharmaceuticals Holdings (PARN) & Sophiris Bio (NASDAQ:SPHS)
Sophiris Bio (NASDAQ: SPHS) and Parnell Pharmaceuticals Holdings (NASDAQ:PARN) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitabiliy, risk, institutional ownership, analyst recommendations and dividends.
Valuation and Earnings
This table compares Sophiris Bio and Parnell Pharmaceuticals Holdings’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Sophiris Bio||N/A||N/A||-$10.78 million||($0.49)||-4.33|
|Parnell Pharmaceuticals Holdings||N/A||N/A||N/A||N/A||N/A|
This is a summary of current ratings for Sophiris Bio and Parnell Pharmaceuticals Holdings, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Parnell Pharmaceuticals Holdings||0||0||0||0||N/A|
Sophiris Bio currently has a consensus price target of $6.60, indicating a potential upside of 211.32%. Given Sophiris Bio’s higher probable upside, research analysts plainly believe Sophiris Bio is more favorable than Parnell Pharmaceuticals Holdings.
Institutional & Insider Ownership
6.1% of Sophiris Bio shares are owned by institutional investors. Comparatively, 16.9% of Parnell Pharmaceuticals Holdings shares are owned by institutional investors. 3.9% of Sophiris Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Sophiris Bio has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Parnell Pharmaceuticals Holdings has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500.
This table compares Sophiris Bio and Parnell Pharmaceuticals Holdings’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Parnell Pharmaceuticals Holdings||-130.46%||-83.86%||-43.24%|
Sophiris Bio beats Parnell Pharmaceuticals Holdings on 5 of the 8 factors compared between the two stocks.
Sophiris Bio Company Profile
Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.
Parnell Pharmaceuticals Holdings Company Profile
Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.